Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway
Mengchen Lu, Tian Liu, Qiong Jiao, et al.
European Journal of Medicinal Chemistry (2018) Vol. 146, pp. 251-259
Closed Access | Times Cited: 250

Showing 1-25 of 250 citing articles:

PROTAC targeted protein degraders: the past is prologue
Miklós Békés, David R. Langley, Craig M. Crews
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 3, pp. 181-200
Open Access | Times Cited: 1867
Targeted protein degradation: expanding the toolbox
Matthieu Schapira, Matthew F. Calabrese, Alex N. Bullock, et al.
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 12, pp. 949-963
Closed Access | Times Cited: 718
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Mariell Pettersson, Craig M. Crews
Drug Discovery Today Technologies (2019) Vol. 31, pp. 15-27
Open Access | Times Cited: 601
An open-source drug discovery platform enables ultra-large virtual screens
Christoph Gorgulla, Andras Boeszoermenyi, Zifu Wang, et al.
Nature (2020) Vol. 580, Iss. 7805, pp. 663-668
Open Access | Times Cited: 525
PROTACs: great opportunities for academia and industry
Xiuyun Sun, Hongying Gao, Yiqing Yang, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 513
Targeted protein degradation: elements of PROTAC design
Stacey-Lynn Paiva, Craig M. Crews
Current Opinion in Chemical Biology (2019) Vol. 50, pp. 111-119
Open Access | Times Cited: 481
Targeted protein degradation: mechanisms, strategies and application
Lin Zhao, Jia Zhao, Kunhong Zhong, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 420
Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1
Adam D. Cotton, Duy Nguyen, Josef A. Gramespacher, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 2, pp. 593-598
Open Access | Times Cited: 344
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Dhanusha A. Nalawansha, Craig M. Crews
Cell chemical biology (2020) Vol. 27, Iss. 8, pp. 998-1014
Open Access | Times Cited: 336
Nrf2/Keap1/ARE signaling: Towards specific regulation
A. V. Ulasov, Andrey A. Rosenkranz, Georgii P. Georgiev, et al.
Life Sciences (2021) Vol. 291, pp. 120111-120111
Open Access | Times Cited: 325
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
Sarah K. Madden, Aline D. de Araujo, Mara Gerhardt, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 308
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
Katherine A. Donovan, Fleur M. Ferguson, Jonathan W. Bushman, et al.
Cell (2020) Vol. 183, Iss. 6, pp. 1714-1731.e10
Open Access | Times Cited: 285
Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities
Marlene F. Schmidt, Zhong Yan Gan, David Komander, et al.
Cell Death and Differentiation (2021) Vol. 28, Iss. 2, pp. 570-590
Open Access | Times Cited: 282
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Rik Ossenkoppele, Rik van der Kant, Oskar Hansson
The Lancet Neurology (2022) Vol. 21, Iss. 8, pp. 726-734
Open Access | Times Cited: 282
Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action
Kristin M. Riching, Sarah D. Mahan, Cesear Corona, et al.
ACS Chemical Biology (2018) Vol. 13, Iss. 9, pp. 2758-2770
Open Access | Times Cited: 266
Degradation of proteins by PROTACs and other strategies
Yang Wang, Xueyang Jiang, Feng Feng, et al.
Acta Pharmaceutica Sinica B (2019) Vol. 10, Iss. 2, pp. 207-238
Open Access | Times Cited: 255
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
Tasuku Ishida, Alessio Ciulli
SLAS DISCOVERY (2020) Vol. 26, Iss. 4, pp. 484-502
Open Access | Times Cited: 255
Current strategies for the design of PROTAC linkers: a critical review
Robert I. Troup, Charlene Fallan, Matthias G. J. Baud
Exploration of Targeted Anti-tumor Therapy (2020) Vol. 1, Iss. 5
Open Access | Times Cited: 254
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
Jiantao Hu, Biao Hu, Mingliang Wang, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 3, pp. 1420-1442
Closed Access | Times Cited: 233
The PROTAC technology in drug development
Yutian Zou, Danhui Ma, Yinyin Wang
Cell Biochemistry and Function (2019) Vol. 37, Iss. 1, pp. 21-30
Open Access | Times Cited: 226
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
Sajid Khan, Yonghan He, Xuan Zhang, et al.
Oncogene (2020) Vol. 39, Iss. 26, pp. 4909-4924
Open Access | Times Cited: 189
Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
Shanique Alabi, Craig M. Crews
Journal of Biological Chemistry (2021) Vol. 296, pp. 100647-100647
Open Access | Times Cited: 189
Four-repeat tauopathies
Thomas W. Rösler, Amir Tayaranian Marvian, Matthias Brendel, et al.
Progress in Neurobiology (2019) Vol. 180, pp. 101644-101644
Closed Access | Times Cited: 184
It’s all about tau
Cheril Tapia‐Rojas, Fabian Cabezas-Opazo, Carol A. Deaton, et al.
Progress in Neurobiology (2018) Vol. 175, pp. 54-76
Open Access | Times Cited: 163
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Zhenyi Hu, Craig M. Crews
ChemBioChem (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 159
Page 1 - Next Page

Scroll to top